REG - ValiRx PLC - Submission of Clinical Trial Application re VAL201 <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

06/09/2014 02:05

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140610:nRSJ2082Ja


RNS Number : 2082J
ValiRx PLC
10 June 2014 
 
10 June 2014 
 
ValiRx Plc 
 
("ValiRx" or "the Company") 
 
Re: Submission of application to progress VAL201 in human patient studies
("CTA") 
 
ValiRx Plc (AIM: VAL), the life science company with a focus on cancer
diagnostics and therapeutics for personalised medicine, is pleased to report
that it has submitted an application to the Medicines and Healthcare Products
Regulatory Agency ("MHRA") for a phase I/II extended clinical study, or trial,
of VAL201 in people with cancer. VAL201 is ValiRx's leading anti-cancer
therapeutic candidate. 
 
The Company and its team of clinical associates and advisors plan to conduct
"A Phase I/II, dose escalation study to assess the safety and tolerability of
VAL201 in patients with locally advanced or metastatic prostate cancer and
other advanced solid tumours." The study takes place at University College
London Hospital when all the consents have been given. The Company will
provide further information as the study progresses. 
 
Dr Satu Vainikka, CEO of ValiRx, commented:  "We are delighted that the team
have taken the VAL201 clinical trial programme to the Human trial stage, but
importantly, have taken the study beyond what was originally envisaged and
onto the threshold of Phase II.  I look forward to further progress and to
updating shareholders accordingly". 
 
- ENDS - 
 
For more information, please contact: 
 
 ValiRx plc                                        Tel: +44 (0) 20 3008 4416          
 Dr Satu Vainikka                                  www.valirx.com                     
                                                                                      
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7148 7900          
 Liam Murray / Avi Robinson                                                           
                                                                                      
 Daniel Stewart & Company Plc (Broker)             Tel: +44 (0) 20 7776 6550          
 David Hart                                                                           
 Peckwater PR                                      Tel: +44 (0) 7879 458 364          
 Tarquin Edwards                                   tarquin.edwards@peckwaterpr.co.uk  
 
 
Notes for Editors 
 
ValiRx Plc 
 
ValiRx Plc is a biopharmaceutical company developing novel technologies and
products in oncology therapeutics and diagnostics. The product focus is in the
epigenomic analysis and treatment of cancer, but the technologies can be
applied to other fields as well, such as neurology and inflammatory diseases. 
 
The Company listed on AIM in October 2006 and is creating a portfolio of
innovative products through investment in specific development projects. It
actively manages projects within this portfolio as a trading company and is
not an investment vehicle. The ValiRx business model spreads the risks of life
science technology developments by minimising financial exposure and running a
set of projects to defined commercial endpoints. This maximises returns to
shareholders by adding value at the earlier stages where value increases per
investment unit are the greatest. 
 
The Company operates through the following divisional companies: 
 
1. ValiFinn is the biomarkers and diagnostic development division 
 
2. ValiPharma is the therapeutics division with two embedded technologies
primarily directed at the treatment of cancers. 
 
This information is provided by RNS
The company news service from the London Stock Exchange